ANIP Q2 Deep Dive: Rare Disease Expansion Drives Growth Amid Guidance Recalibration
Anthony Lee
Tue, August 11, 2026 at 7:03 PM GMT+5:30
5 min read
- ANIP
-1.39%
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results exceeding the market’s revenue expectations , with sales up 25.9% year on year to $266 million. On the other hand, the company’s full-year revenue guidance of $1.11 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.21 per share was 8.2% above analysts’ consensus estimates
Is now the time to buy ANIP? Find out in our full research report (it’s free)
ANI Pharmaceuticals (ANIP) Q2 CY2026 Highlights:
Revenue: $266 million vs analyst estimates of $259.8 million (25.9% year-on-year growth, 2.4% beat)
Adjusted EPS: $2.21 vs analyst estimates of $2.04 (8.2% beat)
Adjusted EBITDA: $71.6 million vs analyst estimates of $63.7 million (26.9% margin, 12.4% beat)
The company reconfirmed its revenue guidance for the full year of $1.11 billion at the midpoint
Management reiterated its full-year Adjusted EPS guidance of $9.44 at the midpoint
EBITDA guidance for the full year is $292.5 million at the midpoint, in line with analyst expectations
Operating Margin: 15.2%, up from 6.6% in the same quarter last year
Market Capitalization: $1.66 billion
StockStory’s Take
ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively to the results. Management highlighted the rapid scale-up of its sales force for Cortrophin Gel and robust demand across existing specialties. CEO Nikhil Lalwani noted, “We are seeing significant momentum in demand in the third quarter with July representing the highest month for new cases initiated,” attributing quarterly performance to persistent execution and expansion efforts.
Looking forward, ANI Pharmaceuticals’ guidance is shaped by the anticipated ramp of its expanded rare disease sales force and the continued penetration of Cortrophin Gel into new specialty areas, particularly gout. Management expects the business to benefit from the full deployment of its newly trained team and strong demand drivers, with Lalwani stating, “We believe we are well-positioned to achieve our revised 2026 guidance based on the continued momentum in existing specialties and the strong demand generation from the gout expansion.” The company also emphasized its confidence in operating leverage from these investments carrying into next year.
Key Insights from Management’s Remarks
Management attributed quarterly growth to sustained momentum in rare disease therapies, the successful scale-up of its sales force, and new product contributions, while also acknowledging a recalibration of guidance to reflect first-half results
